PT1003548E - Dispositivo para a inducao de uma resposta por ctl - Google Patents
Dispositivo para a inducao de uma resposta por ctlInfo
- Publication number
- PT1003548E PT1003548E PT98936827T PT98936827T PT1003548E PT 1003548 E PT1003548 E PT 1003548E PT 98936827 T PT98936827 T PT 98936827T PT 98936827 T PT98936827 T PT 98936827T PT 1003548 E PT1003548 E PT 1003548E
- Authority
- PT
- Portugal
- Prior art keywords
- induction
- antigen
- inducing
- ctl
- ctl response
- Prior art date
Links
- 230000006698 induction Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 210000004324 lymphatic system Anatomy 0.000 abstract 1
- 230000003204 osmotic effect Effects 0.000 abstract 1
- 230000003252 repetitive effect Effects 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Burglar Alarm Systems (AREA)
- General Induction Heating (AREA)
- Memory System Of A Hierarchy Structure (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002209815A CA2209815A1 (en) | 1997-07-10 | 1997-07-10 | Vaccine method using osmotic pump |
US98832097A | 1997-12-10 | 1997-12-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1003548E true PT1003548E (pt) | 2006-09-29 |
Family
ID=25679470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT98936827T PT1003548E (pt) | 1997-07-10 | 1998-07-10 | Dispositivo para a inducao de uma resposta por ctl |
Country Status (10)
Country | Link |
---|---|
EP (3) | EP1003548B1 (pt) |
JP (1) | JP3857877B2 (pt) |
AT (1) | ATE325619T1 (pt) |
AU (1) | AU739189B2 (pt) |
DE (1) | DE69834494T2 (pt) |
ES (2) | ES2438735T3 (pt) |
IL (3) | IL133912A0 (pt) |
NZ (1) | NZ502168A (pt) |
PT (1) | PT1003548E (pt) |
WO (1) | WO1999002183A2 (pt) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6977074B2 (en) | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
ATE497971T1 (de) | 1999-06-04 | 2011-02-15 | Florian Kern | Peptide zur vakzinierung gegen das humane cmv |
AT408721B (de) | 1999-10-01 | 2002-02-25 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung enthaltend ein antigen |
ATE391726T1 (de) * | 1999-10-22 | 2008-04-15 | Sanofi Pasteur Ltd | Modifiziertes gp100 und dessen verwendung |
CA2398816A1 (en) * | 2000-02-04 | 2001-08-09 | Duke University | Human immunodeficiency virus vaccine |
DE10006033B4 (de) | 2000-02-10 | 2005-11-10 | Professor Dr. Magnus von Knebel Doeberitz Chirurgische Universitätsklinik Sektion für Molekulare Diagnostik und Therapie | Immunisierung eines Individuums gegen Carcinome und ihre Vorstufen |
EP1265916B1 (en) * | 2000-03-21 | 2005-12-21 | Genzyme Corporation | Therapeutic anti-cytomegalovirus compounds |
CA2411040A1 (en) | 2000-05-31 | 2001-12-06 | Genzyme Corporation | Therapeutic anti-melanoma compounds |
EP1619207A3 (en) * | 2000-09-01 | 2006-02-08 | Epimmune Inc. | HLA-A2.1 binding peptides derived from HCV and their uses |
EP1195381A1 (de) * | 2000-09-28 | 2002-04-10 | Immusystems GmbH | CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope |
US6773695B2 (en) | 2000-10-05 | 2004-08-10 | Mannkind Corporation | Modulation of allergic response |
EP1752160A3 (en) | 2001-04-06 | 2007-05-30 | Mannkind Corporation | Epitope sequences |
WO2003008537A2 (en) | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
JP3536039B2 (ja) * | 2001-05-08 | 2004-06-07 | 独立行政法人 科学技術振興機構 | Htlv−i腫瘍に対する抗腫瘍抗原又はその抗原エピトープ |
CA2447616A1 (en) * | 2001-05-18 | 2002-11-28 | Deborah Fuller | Vaccine composition |
EP2314712B1 (en) | 2001-11-07 | 2014-01-08 | Mannkind Corporation | Expression vectors encoding epitopes of antigens and methods for their design |
WO2003106616A2 (en) * | 2002-06-12 | 2003-12-24 | Gavish-Galilee Bio Applications Ltd | MEMBRANE-ANCHORED β2 MICROGLOBULIN COVALENTLY LINKED TO MHC CLASS I PEPTIDE EPITOPES |
ATE476196T1 (de) * | 2003-06-17 | 2010-08-15 | Mannkind Corp | Zusammensetzung zur auslösung, verbesserung und erhaltung von immunantworten gegen mhc-klasse-i- beschränkte epitope, für prophylaktische oder therapeutische zwecke |
US9090673B2 (en) * | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
EP2332971B1 (en) | 2004-06-17 | 2016-02-17 | MannKind Corporation | Epitope analogs |
AU2005321905A1 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to bypass CD+4 cells in the induction of an immune response |
CA2594224A1 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
US20060153844A1 (en) | 2004-12-29 | 2006-07-13 | Thomas Kundig | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
US20060159694A1 (en) | 2004-12-29 | 2006-07-20 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in compositions for various types of cancers |
JP5416968B2 (ja) | 2005-06-17 | 2014-02-12 | マンカインド コーポレイション | 癌細胞及び腫瘍間質上に発現される優勢及び亜優勢エピトープに対する多価免疫応答を誘発するための方法及び組成物 |
AU2006259221B8 (en) | 2005-06-17 | 2013-02-07 | Mannkind Corporation | Multivalent entrain-and-amplify immunotherapeutics for carcinoma |
KR20080028938A (ko) | 2005-06-17 | 2008-04-02 | 맨카인드 코포레이션 | 에피토프 유사체 |
EP1820511A1 (en) * | 2006-02-20 | 2007-08-22 | Prolmmune Limited | MHC binding peptides and their uses |
MX2009008620A (es) | 2007-02-15 | 2009-10-22 | Mannkind Corp | Un metodo para mejorar la respuesta de celulas t. |
EP2361930A3 (en) | 2007-03-26 | 2011-10-26 | Dako Denmark A/S | Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases |
EP3023436A1 (en) | 2007-07-03 | 2016-05-25 | Dako Denmark A/S | Improved methods for generation, labeling and use of mhc multimers |
WO2009039854A2 (en) | 2007-09-27 | 2009-04-02 | Dako Denmark A/S | Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics |
WO2009043155A2 (en) * | 2007-10-03 | 2009-04-09 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Distinct hiv-1 gag and env epitopes of hla alleles associated with differential susceptibility to hiv-1 infection |
DK2254592T3 (da) | 2008-02-28 | 2019-09-09 | Dako Denmark As | MHC-multimerer til Borrelia-diagnostik og sygdom |
US10722562B2 (en) | 2008-07-23 | 2020-07-28 | Immudex Aps | Combinatorial analysis and repair |
GB0817244D0 (en) | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
CA2778707A1 (en) | 2009-10-23 | 2011-04-28 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
US10568948B2 (en) | 2015-05-13 | 2020-02-25 | Agenus Inc. | Vaccines for treatment and prevention of cancer |
EP3468581A1 (en) | 2016-06-13 | 2019-04-17 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
AU2018328209A1 (en) | 2017-09-05 | 2020-04-23 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
TW201939514A (zh) | 2018-03-16 | 2019-10-01 | 日商弘泰生物科技股份有限公司 | 免疫實體之有效率的分群 |
EP3784688A2 (en) | 2018-04-26 | 2021-03-03 | Agenus Inc. | Heat shock protein-binding peptide compositions and methods of use thereof |
EP4091627A1 (en) * | 2021-05-21 | 2022-11-23 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Tcr constructs specific for magea4-derived epitopes |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0686030T3 (da) * | 1993-12-23 | 2001-06-25 | Rmf Dictagene Sa | Med antigen ladede mikropartikler og farmaceutiske sammensætninger, som indeholder disse mikropartikler |
-
1998
- 1998-07-10 NZ NZ502168A patent/NZ502168A/xx not_active IP Right Cessation
- 1998-07-10 WO PCT/US1998/014289 patent/WO1999002183A2/en active Application Filing
- 1998-07-10 EP EP98936827A patent/EP1003548B1/en not_active Expired - Lifetime
- 1998-07-10 ES ES06113679.2T patent/ES2438735T3/es not_active Expired - Lifetime
- 1998-07-10 DE DE69834494T patent/DE69834494T2/de not_active Expired - Lifetime
- 1998-07-10 IL IL13391298A patent/IL133912A0/xx unknown
- 1998-07-10 AU AU85689/98A patent/AU739189B2/en not_active Ceased
- 1998-07-10 EP EP06113679.2A patent/EP1787654B1/en not_active Expired - Lifetime
- 1998-07-10 EP EP10178583A patent/EP2286831A1/en not_active Withdrawn
- 1998-07-10 PT PT98936827T patent/PT1003548E/pt unknown
- 1998-07-10 ES ES98936827T patent/ES2265165T3/es not_active Expired - Lifetime
- 1998-07-10 AT AT98936827T patent/ATE325619T1/de active
- 1998-07-10 JP JP2000501773A patent/JP3857877B2/ja not_active Expired - Fee Related
-
2000
- 2000-01-06 IL IL133912A patent/IL133912A/en not_active IP Right Cessation
-
2007
- 2007-03-01 IL IL181687A patent/IL181687A0/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP3857877B2 (ja) | 2006-12-13 |
JP2001509490A (ja) | 2001-07-24 |
EP1787654A1 (en) | 2007-05-23 |
AU739189B2 (en) | 2001-10-04 |
ATE325619T1 (de) | 2006-06-15 |
NZ502168A (en) | 2002-08-28 |
ES2265165T3 (es) | 2007-02-01 |
EP1003548A1 (en) | 2000-05-31 |
EP2286831A1 (en) | 2011-02-23 |
DE69834494T2 (de) | 2007-03-01 |
IL133912A (en) | 2010-12-30 |
WO1999002183A2 (en) | 1999-01-21 |
IL133912A0 (en) | 2001-04-30 |
EP1003548B1 (en) | 2006-05-10 |
ES2438735T3 (es) | 2014-01-20 |
AU8568998A (en) | 1999-02-08 |
IL181687A0 (en) | 2007-07-04 |
DE69834494D1 (de) | 2006-06-14 |
EP1787654B1 (en) | 2013-09-11 |
WO1999002183A3 (en) | 1999-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1003548E (pt) | Dispositivo para a inducao de uma resposta por ctl | |
FI953608A (fi) | Rokoteyhdisteet ja menetelmä immuunireaktion aikaansaamiseksi limakalvossa järjestelmällisellä rokottamisella | |
PT851927E (pt) | Compostos para imunoterapia e diagnostico de tuberculose | |
FI955667A (fi) | Adjuvantteja RS-viruksen vastaisia rokotteita varten | |
ATE422352T1 (de) | Liposomaler grippeimpfstoff und verfahren | |
DK1404363T3 (da) | Adjuvanssammensætning til mucosalt og injektionsfremførte vacciner | |
CY1105684T1 (el) | Ανοσοενισχυτικα εμβολιων | |
DE60012711D1 (de) | Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe | |
MX9207113A (es) | Fragmento de adn, peptido que comprende una proteina superficial ha de un virus de gripe a y vacuna que comprende tal peptido. | |
DK1077722T3 (da) | Fremgangsmåder og produkter til induktion af mukosaimmunitet | |
MA24638A1 (fr) | Vaccin | |
ES2184122T3 (es) | Vacuna polinucleotidica bovina por via intradermica. | |
EP2172551A3 (en) | Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use | |
GB0118532D0 (en) | Materials and methods relating to improved vaccination strategies | |
DE60136928D1 (de) | Verwendung von pflanzen-öl-körper in impfstoffverabreichungsysteme | |
ATE374622T1 (de) | Genetische impstoffe mit adjuvans | |
HUP0002752A2 (hu) | Egy szekréciós vektor alkalmazása termékenység-szabályozásra orális vakcinálással | |
IT1233419B (it) | Peptidi sintetici immunologicamente attivi utili per la preparazione di un vaccino antimalaria | |
ATE274354T1 (de) | Impfungsmethode zur effizienten induktion der t- lymphozyten zytotoxischantwort | |
DE3883211D1 (de) | Steuervorrichtung fuer zahnaerztliche sauganlage. | |
CY1108864T1 (el) | Ενωσεις για ανοσοθεραπεια και διαγνωση φυματιωσης και μεθοδοι χρησεις τους | |
Babiuk | Vaccine delivery systems and immune regulation in modern immunization | |
CY1116907T1 (el) | Ανασυνδυασμενα εμβολια κατα κωπηποδων καλιγιδων (θαλασσιων ψειρων) και αλληλουχιες αντιγονων αυτων | |
IT1255037B (it) | Procedimento per la preparazione di vaccini basato sulla identificazione di sequenze amminoacidiche dell'antigene simili a sequenze amminoacidiche dell'organismo da immunizzare, e vaccini cosi'ottenibili. | |
ATE105483T1 (de) | Impfstoff-adjuvans. |